Cognition Therapeutics (CGTX) News Today $0.67 +0.08 (+13.93%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.44%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s DiseaseJuly 30 at 7:58 AM | finance.yahoo.comCognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's DiseaseJuly 29, 2025 | globenewswire.comCognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comCognition Therapeutics stock soars after DLB study resultsJuly 16, 2025 | in.investing.comCognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAICJuly 16, 2025 | globenewswire.comCognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study ProgressJuly 11, 2025 | insidermonkey.comCognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's DiseaseJuly 11, 2025 | finanznachrichten.deCognition Therapeutics Shares Jump 75% After FDA Discussion on Alzheimer’s TreatmentJuly 11, 2025 | msn.comCognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesineJuly 11, 2025 | msn.comCognition Therapeutics stock soars after FDA meeting on Alzheimer’s drugJuly 10, 2025 | in.investing.comCognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s DiseaseJuly 10, 2025 | finance.yahoo.comCognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDAJuly 10, 2025 | quiverquant.comQCognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's DiseaseJuly 10, 2025 | globenewswire.comCognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial DataJuly 5, 2025 | benzinga.comCGTX - Cognition Therapeutics Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment TargetJuly 1, 2025 | finance.yahoo.comCognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment TargetJuly 1, 2025 | globenewswire.comCognition Therapeutics, Inc. (CGTX) - Yahoo FinanceJune 30, 2025 | finance.yahoo.comCognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)June 25, 2025 | finance.yahoo.comCognition Therapeutics, Inc. Schedules End-of-Phase 2 Meeting with FDA for Alzheimer's Treatment and Files Applications for Breakthrough Status in Dementia with Lewy BodiesJune 25, 2025 | quiverquant.comQCognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)June 25, 2025 | globenewswire.comPhilanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesJune 3, 2025 | finance.yahoo.comPhilanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesJune 3, 2025 | globenewswire.comCognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy BodiesMay 28, 2025 | globenewswire.comCognition announces outcomes from trial of zervimesine for geographic atrophyMay 10, 2025 | finance.yahoo.comCognition Therapeutics presents preclinical data on zervimesine at ARVOMay 9, 2025 | msn.comCognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell HealthMay 9, 2025 | globenewswire.comCognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic AtrophyMay 8, 2025 | finance.yahoo.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business UpdateMay 7, 2025 | finanznachrichten.deCognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business UpdateMay 7, 2025 | globenewswire.comCognition Therapeutics presents results at AD/PD 2025 on CT1812April 2, 2025 | markets.businessinsider.comCognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease ProcessesApril 1, 2025 | markets.businessinsider.comCognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease ProcessesApril 1, 2025 | globenewswire.comCognition to Reveal Biomarker Findings Next WeekMarch 25, 2025 | baystreet.caCognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025March 25, 2025 | globenewswire.comCognition Therapeutics price target lowered to $5 from $6 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comEarnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net lossMarch 22, 2025 | uk.investing.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comCognition Therapeutics price target lowered to $8 from $11 at ChardanMarch 21, 2025 | markets.businessinsider.comCognition Therapeutics Earnings Call: Progress Amid ChallengesMarch 21, 2025 | tipranks.comCognition Therapeutics Advances Alzheimer’s and DLB TrialsMarch 20, 2025 | tipranks.comCognition Therapeutics reports FY24 EPS (86c), consensus (74c)March 20, 2025 | markets.businessinsider.comCognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comCognition Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comCognition Therapeutics shifts to Nasdaq Capital MarketMarch 14, 2025 | investing.comCognition Therapeutics to Report Fourth Quarter and Full Year 2024 ResultsMarch 13, 2025 | globenewswire.comCognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange ListingMarch 12, 2025 | globenewswire.comCognition Therapeutics to Present at Life Sciences Virtual Investor ConferenceMarch 10, 2025 | globenewswire.comCognition Therapeutics, Inc.: Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMDFebruary 27, 2025 | finanznachrichten.deCognition Therapeutics publishes research on zervimesine in dry AMDFebruary 27, 2025 | markets.businessinsider.com Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CGTX Media Mentions By Week CGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼-0.330.52▲Average Medical News Sentiment CGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼32▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Instil Bio News Today GENFIT News Today Organigram Global News Today Eupraxia Pharmaceuticals News Today Semper Paratus Acquisition News Today CytomX Therapeutics News Today enGene News Today Kyverna Therapeutics News Today Innate Pharma News Today China SXT Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
